News >

Nivolumab/Ipilimumab Approval in Advanced HCC Calls for Nuanced Look at Available Data

Caroline Seymour
Published: Monday, Mar 16, 2020

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

Ghassan K. Abou-Alfa, MD

The armamentarium in advanced hepatocellular carcinoma (HCC) is rapidly evolving as evidenced by the recent accelerated approval of the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in the second-line setting. While the approval signals a step in the right direction, more data are needed before the regimen can be appropriately sequenced into practice, according to Ghassan K. Abou-Alfa, MD.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x